Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States

被引:0
作者
Karen Seiter
Dominick Latremouille-Viau
Annie Guerin
Briana Ndife
Karen Habucky
Derek H. Tang
Irina Pivneva
Patrick Gagnon-Sanschagrin
George J. Joseph
机构
[1] New York Medical College,
[2] Analysis Group,undefined
[3] Inc.,undefined
[4] Novartis Pharmaceuticals Corporation,undefined
来源
Advances in Therapy | 2018年 / 35卷
关键词
Chronic myeloid leukemia; Costs; Dasatinib; Infections; Healthcare resource utilization; Nilotinib; Oncology;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1671 / 1685
页数:14
相关论文
共 186 条
  • [1] Bartram CR(1983)Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia Nature 306 277-1459
  • [2] de Klein A(2015)Chronic myeloid leukaemia Lancet 385 1447-S140
  • [3] Hagemeijer A(2015)Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients Ann Hematol 94 S133-1129
  • [4] van Agthoven T(2012)Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) Blood 119 1123-2541
  • [5] van Kessel AG(2006)Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias N Engl J Med 354 2531-2203
  • [6] Bootsma D(2012)Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up Leukemia 26 2197-2259
  • [7] Apperley JF(2010)Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia N Engl J Med 362 2251-2270
  • [8] Hochhaus A(2010)Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 362 2260-50
  • [9] Ernst T(2016)The role of new tyrosine kinase inhibitors in chronic myeloid leukemia Cancer J 22 40-68
  • [10] Eigendorff E(2010)infectious events in patients with chronic myeloid leukemia treated with nilotinib as a front line therapy and after imatinib failure Blood. 116 1233-1535